Bulletin from the annual general meeting of Xspray Pharma AB (publ)

Adoption of income statement and balance sheet for the financial year 2018 and discharge from liability The AGM resolved to adopt the income statement for the financial year 2018 as well as the balance sheet and consolidated balance sheet as of 31 December 2018. The members of the board of directors and the managing director […]

Read more

Kerstin Hasselgren appointed CFO at Xspray Pharma

STOCKHOLM – May 3, 2019. Xspray Pharma (Nasdaq First North: XSPRAY) today announces that Kerstin Hasselgren has been appointed CFO of the company. Kerstin has extensive experience from working in publicly listed international companies, including positions as Vice President Finance at AstraZeneca within Global R&D and Global Operations. Most recently, Kerstin comes from a position as […]

Read more

Notice of annual general meeting of Xspray Pharma AB (publ)

Right to attend the annual general meeting Shareholders who wish to attend the annual general meeting must: – be registered in the share register maintained by Euroclear Sweden AB on Friday 17 May 2019, and must also – notify the company of their intention to attend the meeting, no later than Friday 17 May 2019. […]

Read more

Xspray Pharma announces positive clinical data for the drug candidate HyNap-Sora

In the completed Phase I clinical trial in 14 healthy subjects, bioavailability of two different formulations of HyNap-Sora was assessed in comparison with Nexavar. The results are positive and the study achieved its primary purpose to show increased bioavailability compared to the originator product. In addition, and as shown in earlier studies with Xspray’s lead […]

Read more

Xspray Pharma has carried out a directed share issue raising gross proceeds of approximately SEK 92 million

A group of Swedish and international institutional investors, among others Unionen, Third Swedish National Pension Fund and Forth Swedish National Pension Fund, have subscribed for shares in the directed share issue. The Company believes that the flexibility of a placing without pre-emption right for existing shareholders is the most appropriate way to diversify the shareholder […]

Read more

Xspray Pharma contemplates a directed share issue to continue development of its product portfolio

The directed share issue in brief The directed share issue is intended to be conducted through an accelerated book-building procedure, based on the authorization given by Xspray’s annual general meeting that was held on 14 May 2018, and may entail an issue of approximately 1.3 million new shares (corresponding to approximately 9.5 percent of the […]

Read more

Additional product patent in the United States for HyNap-Dasa

 “This new patent approval in our most important market further confirms our innovative development work. Together with the previously communicated formal clinical bioequivalence for the company´s lead product candidate, HyNap-Dasa, this patent will be instrumental in our forthcoming negotiations with potential partners,” says Per Andersson, CEO of Xspray. Xspray strives to obtain patents both for […]

Read more

Resolution on long-term incentive programme at extraordinary general meeting in Xspray Pharma on 28 November 2018

LTI 2018 includes around 17 persons. The company’s board members are not included in LTI 2018. The right to subscribe for warrants shall, by way of deviation from the preferential right of the shareholders, be vested in the CEO, senior executives and other people employed by the company or who has entered into employee agreements […]

Read more

Xspray Pharma’s nomination committee for the annual general meeting 2019

The nomination committee, which has been appointed in accordance with the principles adopted by the annual general meeting on 14 May 2018, consists of: · Gillis Cullin, appointed by Östersjöstiftelsen  · Anders Bladh, appointed by Ribbskottet AB  · Niclas Eriksson, appointed by Niclas Eriksson Family and holding companies  · Michael Wolff Jensen (chairman of the […]

Read more

Xspray Pharma prepares for listing on main list

The company’s board and management will now initiate the work required to prepare the company for listing on the main list. The goal is to complete the up-listing within the next twelve months. “We feel that Xspray is mature for a listing on the main list. It increases the company’s ability to attract institutional owners […]

Read more